

**Section:** This is a revision to Section VIII. Scientific Studies and Analyses. D. Clinical Studies. 3. Individual Study Summaries 1. (MRTPA), i. (PMTA) Evaluation of the Abuse Liability of Very Low Nicotine Cigarettes (NCT0359751) and 2. (MRTPA), ii (PMTA) and Evaluation of the Abuse Liability of Very Low Nicotine Mentholated Cigarettes (NCT03559725)

**Reason for Revision:** To provide supplemental information, namely the point of contact and telephone number of the clinical and bioanalytic laboratories associated with the “*Evaluation of the Abuse Liability of VLN Cigarettes with Characterization of Nicotine Exposure Profiles in Adult Smokers.*”

**Confidentiality:** A version with proposed redactions is also being submitted.

The Point of Contact for the Bioanalytic Laboratory associated with the studies named above (NCT0359751 and NCT03559725) is

Véronik Gill  
Bioanalytical Principal Investigator (BPI)  
Algorithme Pharma  
575 Armand-Frappier Blvd.  
Laval, Quebec, Canada  
H7V 4B3  
t (b) (6)  
m (b) (6)  
email: (b) (6)@altasciences.com

The Point of Contact for the Clinical Laboratory associated with the studies named above (NCT0359751 and NCT03559725) is

(b) (6) D.O., M.P.H  
Quest Diagnostics – Kansas Business Unit  
10101 Renner Blvd  
Lenexa, KS 66219  
Office: (b) (6)  
Email: (b) (6)@questdiagnostics.com